About Molecular Design & Generation
The Molecular Design & Generation category is part of the AI Drug Discovery market map, tracking 13 companies building in this segment. Target discovery, molecular design, protein folding, and clinical trial optimization accelerating the path from lab to patient. Curated by Hartmann Capital's venture research team.
Companies in Molecular Design & Generation
- Insilico Medicine — Series E, $400M
- Atomwise — Series C, $219M
- Genesis Therapeutics — Series B, $327M
- Iambic Therapeutics — Series B, $327M
- PostEra — Series A, $26M
- Iktos — Series A, $18M
- Entos — Series A, $54M
- Terray Therapeutics — Series B, $180M
- Charm Therapeutics — Series B, $150M
- Peptilogics — Series B2, $113M
- Relay Therapeutics — Public, $520M
- Proxima (VantAI) — Seed, $80M
- Menten AI — Seed, $4M
Frequently Asked Questions
- What companies are in the Molecular Design & Generation category?
- The Molecular Design & Generation category includes 13 companies: Insilico Medicine, Atomwise, Genesis Therapeutics, Iambic Therapeutics, PostEra, Iktos, Entos, Terray Therapeutics, Charm Therapeutics, Peptilogics, Relay Therapeutics, Proxima (VantAI), Menten AI. This is part of the AI Drug Discovery market map maintained by Hartmann Capital.
- How many Molecular Design & Generation startups are tracked?
- Hartmann Capital tracks 13 companies in the Molecular Design & Generation segment of the AI Drug Discovery market map.
- What are the best funded Molecular Design & Generation companies?
- Top funded companies in Molecular Design & Generation include Relay Therapeutics ($520M), Insilico Medicine ($400M), Genesis Therapeutics ($327M), Iambic Therapeutics ($327M), Atomwise ($219M). Browse the full list in the AI Drug Discovery market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.